

## Repligen Corporation (RGEN)

**\$102.43** (As of 02/03/20)

Price Target (6-12 Months): **\$118.00**

Long Term: 6-12 Months

**Zacks Recommendation:**

**Outperform**

(Since: 12/31/19)

Prior Recommendation: Neutral

Short Term: 1-3 Months

**Zacks Rank:** (1-5)

**1-Strong Buy**

Zacks Style Scores:

VGM:D

Value: F

Growth: B

Momentum: F

### Summary

Repligen is progressing well with its filtration and chromatography product franchisees, which recorded organic revenue growth of more than 40% each in third-quarter 2019. In May, Repligen acquired C Technologies, which added a fourth franchise, process analytics — which should drive revenues in the future quarters. The company raised its annual projection for revenues and earnings thrice in 2019. However, the bioprocessing market is highly competitive and is subject to a rapid change through product introductions. Moreover, the company is witnessing a slowdown in its proteins business after exceptional growth in the first half of 2019, which is a concern. Shares have outperformed the industry in the past year. Estimates looks stable ahead of Q4 earnings release. Repligen has a positive record of earnings surprises in the recent quarters.


### Price, Consensus & Surprise



### Data Overview

52 Week High-Low	<b>\$102.85 - \$52.87</b>
20 Day Average Volume (sh)	<b>300,779</b>
Market Cap	<b>\$5.3 B</b>
YTD Price Change	<b>10.7%</b>
Beta	<b>1.25</b>
Dividend / Div Yld	<b>\$0.00 / 0.0%</b>
Industry	<b>Medical - Biomedical and Genetics</b>
Zacks Industry Rank	<b>Top 29% (74 out of 254)</b>

### Sales and EPS Growth Rates (Y/Y %)



Last EPS Surprise	<b>30.0%</b>
Last Sales Surprise	<b>5.1%</b>
EPS F1 Est- 4 week change	<b>0.0%</b>
Expected Report Date	<b>02/20/2020</b>
Earnings ESP	<b>0.0%</b>
P/E TTM	<b>96.6</b>
P/E F1	<b>92.3</b>
PEG F1	<b>5.3</b>
P/S TTM	<b>21.1</b>

### Sales Estimates (millions of \$)

	Q1	Q2	Q3	Q4	Annual*
2020	74 E	79 E	81 E	84 E	317 E
2019	61 A	71 A	69 A	68 E	269 E
2018	45 A	48 A	50 A	52 A	194 A

### EPS Estimates

	Q1	Q2	Q3	Q4	Annual*
2020	\$0.28 E	\$0.30 E	\$0.30 E	\$0.30 E	\$1.11 E
2019	\$0.28 A	\$0.31 A	\$0.26 A	\$0.18 E	\$1.03 E
2018	\$0.17 A	\$0.16 A	\$0.20 A	\$0.21 A	\$0.73 A

\*Quarterly figures may not add up to annual.

The data in the charts and tables, including the Zacks Consensus EPS and Sales estimates, is as of 02/03/2020. The reports text is as of 02/04/2020.


## Overview

Waltham, MA-based Repligen Corporation is a leading provider of advanced bioprocessing technologies and solutions used by large biopharmaceutical companies and contract manufacturing organizations for manufacturing biologic drugs, such as monoclonal antibodies (mAbs) and gene therapies.

Repligen earns revenues from the sale of several products, which can be categorized mainly under three segments, namely Filtration, Chromatography and Protein products. The chromatography products include OPUS and OPUS PD chromatography columns, chromatography resins and ELISA test kits. Filtration products consist of XCell ATF Systems and consumables, KrosFlo filtration products and SIUS filtration products. Protein products comprise the Protein A ligands and cell culture growth factors.

In May 2019, the company acquired privately held bioprocess analytics company C Technologies for \$240 million in a cash-and-stock deal. The acquisition marks Repligen's entry into process analytics and adds its fourth franchise by the name Process Analytics products.

For 2018, the company generated total revenues of \$194.0 million, reflecting a year-over-year gain of 37%. Overall, organic revenue growth was 17% last year.



---

## Reasons To Buy:

- ▲ **Shares Outperforming Industry:** Shares of Repligen have outperformed the industry in the past year. The stock has soared 76.1% against the industry's decrease of 8.9%.
- ▲ **Encouraging Performance in First Nine Months:** In the first nine months of 2019, Repligen witnessed strong organic revenue growth. Following such encouraging results, the company raised its annual projection for revenues and earnings thrice this year. For 2019, it expects sales in the range of \$267-\$270 million, implying organic growth of 31-32%.

Repligen's two product franchises displayed strength in the first nine months of 2019 with filtration and chromatography business recording organic revenue growth of more than 40% each in the period.

Throughout the first nine months of 2019, order load remained strong and the company expects this momentum to continue in the upcoming quarters as well.

- ▲ **Biologics Drugs — A Fast Growing Area:** Repligen's end market, which constitutes biologic drugs, is one of the fastest-growing areas of pharmaceutical research. Only a small number of biologic drugs are approved from a few companies. This indicates the prevalence of an untapped market potential. The global biologics market consistently experiences strong growth and an expansion that has resulted in a need for advanced bioprocess technology, especially with rising demand for customized medicines. The company aims to be a trusted partner in bioprocess technology market for which the future looks promising.
- ▲ **C Technologies Acquisition Holds Promise:** The acquisition of C Technologies added a fourth franchise for Repligen, namely process analytics with focus on at-line and in-line protein concentration measurement. C Technologies is expected to add \$16-\$17 million to Repligen's revenues in about seven months of ownership in 2019. This is a huge positive for the company and to reflect the same, Repligen increased 2019 revenue guidance.

Repligen also has a strong cash position and therefore attractive acquisitions in this speedily-growing space cannot be ruled out.

---

Repligen's three product franchisees are generating significant revenues. C Technologies acquisition holds promise.

---

## Risks

- **Protein Business Set to Slow Down:** Though Repligen had an encouraging first half of 2019, the company expects a slowdown in sales in its proteins business during the second half. It expects the proteins business to remain flat year over year as that has already secured substantial annual demand during the first half of 2019.
  - **Competition in Bioprocessing Market:** Repligen is likely to face fierce competition as many of its contenders may prove to be more successful in their production, marketing and commercialization activities. Bioprocessing products compete on the basis of quality, performance, cost-effectiveness and application suitability with numerous established technologies.
-

## Last Earnings Report

### Repligen Beats on Q3 Earnings, Lifts 2019 Guidance

Repligen reported third-quarter 2019 earnings per share of 26 cents, beating the Zacks Consensus Estimate of 20 cents. The figure also surpassed the year-ago earnings of 20 cents.

The company's total revenues of \$69.4 million surpassed the Zacks Consensus Estimate of \$66 million. Additionally, the top line surged 40% year over year (42% at constant currency) on strong performance by the filtration and chromatography product franchises.

Excluding the impact of currency and acquisitions/divestitures, Repligen's revenues grew 28% organically year over year.

#### Quarter in Detail

In the reported quarter, adjusted research and development expenses were \$5.1 million, up 41.7% from the year-ago figure.

Adjusted selling, general and administrative expenses were \$18.7 million, reflecting an increase of 48.4% year over year.

As of Sep 30, 2019, Repligen had cash and cash equivalents of \$513.5 million compared with \$ 208.9 million at the end of Jun 30, 2019.

#### 2019 Guidance

Repligen raised its previously issued annual forecast for revenues and earnings.

The company expects sales in the range of \$267-\$270 million, implying organic growth of 31-32%. Previously, revenues were expected in the range of \$ 264-\$268 million, indicating organic revenue growth of 29-31%.

Adjusted net income is projected in the range of \$50-\$52 million, lifted from the previous guidance of \$47-\$49 million. Adjusted income from operations is anticipated in the band of \$62-\$64 million, upped from \$60-\$62 million expected previously.

Adjusted EPS is envisioned in the range of \$1-\$1.04, raised from the previous view of 94-98 cents.

Quarter Ending **09/2019**

Report Date	Oct 31, 2019
Sales Surprise	5.06%
EPS Surprise	30.00%
Quarterly EPS	0.26
Annual EPS (TTM)	1.06

---

## Recent News

### Completes Public Offering of Common Stock — Jul 19

Repligen announced that it has closed a public offering of 1,587,000 common shares at \$87 per share for a gross proceed of almost \$138.1 million and an aggregate \$250 million of 0.375% convertible senior notes due 2024.

### Completes C Technologies Acquisition — May 31

Repligen announced that it has concluded the previously announced buyout of the privately held bioprocess analytics company C Technologies for a \$240-million cash-and-stock deal. The acquisition marks Repligen's foray into process analytics and the addition of a fourth franchise

---

## Valuation

Repligen's shares are up 76.1% over the trailing 12-month period. Over the past year, the Zacks sub-industry and the sector are down 8.9% and 0.7%, respectively.

The S&P 500 index is up 16.8% in the past year.

The stock is currently trading at 5.10X trailing 12-month book value, which compares to 3.65X for the Zacks sub-industry, 4.41X for the Zacks sector and 4.40X for the S&P 500 index.

Over the past five years, the stock has traded as high as 12.36X and as low as 1.92X, with a 5-year median of 5.82X. Our Outperform recommendation indicates that the stock will perform better than the market. Our \$118.00 price target reflects 5.87X trailing 12-month book value.

The table below shows summary valuation data for RGEN

Valuation Multiples - RGEN					
		Stock	Sub-Industry	Sector	S&P 500
P/B TTM	Current	5.1	3.65	4.41	4.4
	5-Year High	12.36	5.79	5.03	4.54
	5-Year Low	1.92	2.43	3.43	2.85
	5-Year Median	5.82	3.27	4.29	3.62
P/S F12M	Current	21	2.65	3.05	3.51
	5-Year High	21	5.03	4.16	3.63
	5-Year Low	8.07	2.12	2.7	2.48
	5-Year Median	12.7	2.65	3.27	3.16

As of 02/03/2020

---

## Industry Analysis Zacks Industry Rank: Top 29% (74 out of 254)



## Top Peers

Puma Biotechnology, Inc. (PBYI)	Outperform
Agios Pharmaceuticals, Inc. (AGIO)	Neutral
Allergan plc (AGN)	Neutral
Amgen Inc. (AMGN)	Neutral
Danaher Corporation (DHR)	Neutral
Exelixis, Inc. (EXEL)	Neutral
ImmunoGen, Inc. (IMGN)	Neutral
MacroGenics, Inc. (MGNX)	Neutral

Industry Comparison Industry: Medical - Biomedical And Genetics				Industry Peers		
	RGEN Outperform	X Industry	S&P 500	DHR Neutral	MGNX Neutral	PBYI Outperform
<b>VGM Score</b>	<b>D</b>	-	-	<b>D</b>	<b>D</b>	<b>C</b>
Market Cap	5.33 B	194.54 M	23.66 B	115.64 B	471.47 M	313.25 M
# of Analysts	8	3	13	8	7	4
Dividend Yield	0.00%	0.00%	1.82%	0.42%	0.00%	0.00%
<b>Value Score</b>	<b>F</b>	-	-	<b>D</b>	<b>F</b>	<b>D</b>
Cash/Price	0.10	0.23	0.04	0.17	0.56	0.36
EV/EBITDA	115.34	-3.38	13.87	25.82	-1.51	-3.36
PEG Ratio	5.27	1.70	1.97	2.55	NA	NA
Price/Book (P/B)	5.10	3.77	3.24	4.03	1.85	18.20
Price/Cash Flow (P/CF)	91.48	12.99	13.40	25.91	NA	NA
P/E (F1)	92.28	29.25	18.48	29.62	NA	NA
Price/Sales (P/S)	21.10	13.68	2.60	5.80	8.60	1.12
Earnings Yield	1.08%	-16.04%	5.40%	3.37%	-34.99%	-17.41%
Debt/Equity	0.25	0.02	0.72	0.75	0.11	6.84
Cash Flow (\$/share)	1.12	-1.08	6.92	6.21	-3.86	-2.79
<b>Growth Score</b>	<b>B</b>	-	-	<b>C</b>	<b>D</b>	<b>B</b>
Hist. EPS Growth (3-5 yrs)	37.95%	16.51%	10.80%	2.72%	NA	NA
Proj. EPS Growth (F1/F0)	7.26%	7.31%	7.46%	22.96%	0.67%	34.66%
Curr. Cash Flow Growth	30.32%	19.71%	10.59%	-1.09%	1,216.13%	-63.27%
Hist. Cash Flow Growth (3-5 yrs)	20.59%	7.72%	8.55%	5.87%	NA	-50.86%
Current Ratio	16.03	5.12	1.21	5.19	4.79	1.71
Debt/Capital	19.69%	3.95%	42.91%	41.54%	10.07%	87.25%
Net Margin	9.28%	-197.98%	11.76%	15.09%	-303.08%	-33.90%
Return on Equity	6.50%	-64.16%	17.24%	11.50%	-59.67%	-325.89%
Sales/Assets	0.25	0.20	0.55	0.35	0.15	1.06
Proj. Sales Growth (F1/F0)	17.74%	17.19%	4.22%	6.52%	60.71%	-8.07%
<b>Momentum Score</b>	<b>F</b>	-	-	<b>C</b>	<b>A</b>	<b>A</b>
Daily Price Chg	2.03%	0.37%	0.67%	0.08%	4.11%	2.29%
1 Week Price Chg	1.29%	-3.24%	-2.60%	-0.85%	-14.35%	-2.96%
4 Week Price Chg	9.09%	-0.12%	-0.76%	4.13%	-10.34%	-0.25%
12 Week Price Chg	24.55%	11.77%	2.84%	19.68%	21.21%	-5.63%
52 Week Price Chg	75.94%	-10.96%	13.93%	46.91%	-15.15%	-71.01%
20 Day Average Volume	300,779	211,909	1,915,782	2,355,823	412,911	1,590,219
(F1) EPS Est 1 week change	0.00%	0.00%	0.00%	-0.06%	0.00%	0.00%
(F1) EPS Est 4 week change	0.00%	0.00%	0.00%	-2.11%	8.06%	0.00%
(F1) EPS Est 12 week change	-0.99%	0.00%	-0.13%	-3.52%	7.34%	17.46%
(Q1) EPS Est Mthly Chg	0.00%	0.00%	0.00%	-5.21%	-5.47%	NA

## Zacks Style Scores

The Zacks Style Score is as a complementary indicator to the Zacks rating system, giving investors a way to focus on the highest rated stocks that best fit their own stock picking preferences.

Academic research has proven that stocks with the best Value, Growth and Momentum characteristics outperform the market. The Zacks Style Scores rate stocks on each of these individual styles and assigns a rating of A, B, C, D and F. We also produce the VGM Score (V for Value, G for Growth and M for Momentum), which combines the weighted average of the individual Style Scores into one score. This is perfectly suited for those who want their stocks to have the best scores across the board.

Value Score	F
Growth Score	B
Momentum Score	F
VGM Score	D

As an investor, you want to buy stocks with the highest probability of success. That means buying stocks with a Zacks Recommendation of Outperform, which also has a Style Score of an A or a B.

## Disclosures

**This report contains independent commentary to be used for informational purposes only. The analysts contributing to this report do not hold any shares of this stock. The analysts contributing to this report do not serve on the board of the company that issued this stock. The EPS and revenue forecasts are the Zacks Consensus estimates, unless indicated otherwise on the reports first page.** Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts personal views as to the subject securities and issuers. ZIR certifies that no part of the analysts compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report.

Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Any opinions expressed herein are subject to change.

ZIR is not an investment advisor and the report should not be construed as advice designed to meet the particular investment needs of any investor. Prior to making any investment decision, you are advised to consult with your broker, investment advisor, or other appropriate tax or financial professional to determine the suitability of any investment. This report and others like it are published regularly and not in response to episodic market activity or events affecting the securities industry.

This report is not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned. ZIR or its officers, employees or customers may have a position long or short in the securities mentioned and buy or sell the securities from time to time. ZIR is not a broker-dealer. ZIR may enter into arms-length agreements with broker-dealers to provide this research to their clients. Zacks and its staff are not involved in investment banking activities for the stock issuer covered in this report.

ZIR uses the following rating system for the securities it covers. **Outperform-** ZIR expects that the subject company will outperform the broader U.S. equities markets over the next six to twelve months. **Neutral-** ZIR expects that the company will perform in line with the broader U.S. equities markets over the next six to twelve months. **Underperform-** ZIR expects the company will underperform the broader U.S. equities markets over the next six to twelve months.

No part of this report can be reprinted, republished or transmitted electronically without the prior written authorization of ZIR.